ArticleRevista medica del Instituto Mexicano del Seguro Social2025
[Comment on the article: "Diagnostic performance of the FINDRISC questionnaire to identify insulin resistance in adults"].
Article in Revista medica del Instituto Mexicano del Seguro Social, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The FINDRISC test is a scale developed in Finland by Lindström and Tuomilehto to determine a patient's risk of developing type 2 diabetes. This scale has been accepted and valid in many countries, including Spain, Greece, Norway, and Germany. Having widely accepted instruments opens the possibility of conducting studies between different countries or cultures, which implies evaluating the various items of the instrument in the most accurate way possible. It is important to note that in Mexico, according to ENSANUT 2022, the prevalence of diagnosed diabetes was 12.6% and that of undiagnosed diabetes was 5.8%, resulting in a total prevalence of diabetes of 18.3%. In contrast, in Finland, for the year 2021, the prevalence was 7.7%, which denotes a large difference in the number of people living with diabetes in both countries.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.